Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORCHLIGHT: Toripalimab + Nab-Paclitaxel in Metastatic or Recurrent Triple-Negative Breast Cancer
NCT04085276Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Dec 2018
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in triple-negative breast cancer (TNBC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Dec 2018; status: completed.
02
Drugs
toripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04085276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085276.